Cat. No：GM-60293AB
Product：Anti-CTLA-4/PD-1 hIgG1 Bispecific Antibody(Cadonilimab)
Cat. No：GM-60293AB
Product：Anti-CTLA-4/PD-1 hIgG1 Bispecific Antibody(Cadonilimab)
GM-60293AB-10 10 μg
GM-60293AB-100 100 μg
GM-60293AB-1000 1mg
Species Reactivity Human
Specificity Detects human CTLA-4 and PD-1.
Source/Isotype Monoclonal human IgG1, κ
Application Binding activation: 100 pg/mL-100 μg/mL
Background PD-1 is an immunosuppressive receptor expressed by activated T and B cells and plays a key role in the regulation of the immune response to tumor antibodies and autoantigens. The interaction between PD-1 and its ligand PD-L1 or PD-L2 in neighboring cells can inhibit the conduction of TCR signaling pathway and the effects of TCR-mediated cell proliferation, transcriptional activation, and cytokine production. Therapeutic antibodies and Fc fusion proteins used to block PD-1/PD-L1 interactions have been shown to be promising in clinical trials for the treatment of various cancers.
CTLA-4, also known as CD152, is an immunosuppressive receptor that is constitutively expressed on regulatory T cells (TreGs). It plays a key role in the regulation of immune response. When CTLA4 is upregulated on T cell surface, T cells bind to CD80(B7-1) or CD86(B7-2) with a higher affinity than CD28's positive costimulatory signal, thus inducing T cell nonreactivity. Antibodies and Fc fusion proteins that block the interaction of CTLA4/CD80 and CD86 have been shown to have promising applications in clinical trials against various cancers.
Storage Store at +4℃ short term (1-2 weeks). Store at -20℃ long term
Formulation Phosphate-buffered solution, pH 7.2.
Cat. No：GM-60293AB
Product：Anti-CTLA-4/PD-1 hIgG1 Bispecific Antibody(Cadonilimab)
GM-60293AB-10 10 μg
GM-60293AB-100 100 μg
GM-60293AB-1000 1mg
Species Reactivity Human
Specificity Detects human CTLA-4 and PD-1.
Source/Isotype Monoclonal human IgG1, κ
Application Binding activation: 100 pg/mL-100 μg/mL
Background PD-1 is an immunosuppressive receptor expressed by activated T and B cells and plays a key role in the regulation of the immune response to tumor antibodies and autoantigens. The interaction between PD-1 and its ligand PD-L1 or PD-L2 in neighboring cells can inhibit the conduction of TCR signaling pathway and the effects of TCR-mediated cell proliferation, transcriptional activation, and cytokine production. Therapeutic antibodies and Fc fusion proteins used to block PD-1/PD-L1 interactions have been shown to be promising in clinical trials for the treatment of various cancers.
CTLA-4, also known as CD152, is an immunosuppressive receptor that is constitutively expressed on regulatory T cells (TreGs). It plays a key role in the regulation of immune response. When CTLA4 is upregulated on T cell surface, T cells bind to CD80(B7-1) or CD86(B7-2) with a higher affinity than CD28's positive costimulatory signal, thus inducing T cell nonreactivity. Antibodies and Fc fusion proteins that block the interaction of CTLA4/CD80 and CD86 have been shown to have promising applications in clinical trials against various cancers.
Storage Store at +4℃ short term (1-2 weeks). Store at -20℃ long term
Formulation Phosphate-buffered solution, pH 7.2.
